Status:

COMPLETED

Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases

Lead Sponsor:

Medical University of Graz

Conditions:

Myeloproliferative Disorder

Myelodysplastic Syndromes

Eligibility:

All Genders

18-95 years

Brief Summary

Myelodysplastic and myeloproliferative Disease represent conditions with increased risk for pulmonary hypertension. However, the exact prevalence of pulmonary hypertension in these conditions is not k...

Detailed Description

For early recognition of pulmonary hypertension exercise doppler echocardiography will be used in all patients. Patients with elevated pulmonary arterial pressure at rest or during exercise (estimated...

Eligibility Criteria

Inclusion

  • myelodysplastic disease or myeloproliferative diseases

Exclusion

  • known pulmonary hypertension
  • relevant pulmonary disease
  • relevant left cardiac or valvular disease
  • recent major operations
  • recent changes in medications
  • relevant anaemia
  • inability to exercise

Key Trial Info

Start Date :

April 1 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 1 2011

Estimated Enrollment :

86 Patients enrolled

Trial Details

Trial ID

NCT00909467

Start Date

April 1 2009

End Date

November 1 2011

Last Update

March 9 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medical University of Graz, Pulmonology

Graz, Austria, 8036